Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: A pilot study for breast cancer prevention

Cancer Epidemiology Biomarkers and Prevention

Volumn 11, Issue 7, 2002, Pages 614-621

  Harper Wynne, Catherine ^a   Ross, Gillian ^a   Sacks, Nigel ^a   Salter, Janine ^a   Nasiri, Nazar ^a   Iqbal, Jhangir ^a   A'Hern, Roger ^a   Dowsett, Mitch ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; ESTRADIOL; ESTROGEN RECEPTOR; KI 67 ANTIGEN; LETROZOLE; PEPTIDE; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AFFECTIVE NEUROSIS; AGED; ARTHROPATHY; ARTICLE; BONE METABOLISM; BREAST BIOPSY; BREAST CANCER; BREAST EPITHELIUM; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG WITHDRAWAL; ESTRADIOL BLOOD LEVEL; FEMALE; HEADACHE; HOT FLUSH; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; INSOMNIA; LETHARGY; LIPID METABOLISM; OSTEOLYSIS; PILOT STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROPHYLAXIS; SKIN MANIFESTATION; VERTIGO;

ADMINISTRATION, ORAL; AGED; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; BREAST DISEASES; BREAST NEOPLASMS; CELL DIVISION; CONFIDENCE INTERVALS; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; NITRILES; ODDS RATIO; POSTMENOPAUSE; PRIMARY PREVENTION; PROBABILITY; RECEPTORS, ESTROGEN; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TRIAZOLES;

EID: 0036317949     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Effects of sex steroids on proliferation in normal mammary tissue
2. BRCA1 and BRCA2: From molecular genetics to clinical medicine
3. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-I Study
4. Developmental, cellular, and molecular basis of human breast cancer
5. Increased cell division is a cause of human cancer
6. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
7. Effect of body size on breast-cancer risk among Japanese women
8. Waist circumference, waist:hip ratio, and risk of breast cancer in the Nurses' Health Study
9. Body fat distribution and obesity in pre- and postmenopausal breast cancer
10. Endogenous estrogen and postmenopausal breast cancer: A quantitative review
11. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women
12. Serum sex hormone levels after menopause and subsequent breast cancer
13. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk
14. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey
15. Estrogens as endogenous genotoxic agents: DNA adducts and mutations
16. Endogenous estrogens as carcinogens through metabolic activation
17. Aromatase inhibitors come of age
18. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a Phase III study of the International Letrozole Breast Cancer Group
19. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a Phase III randomized trial
20. Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor
21. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer
22. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response
23. Steroid hormone receptors and carcinoma of the breast
24. Insulin-like growth factors in human breast cancer
25. Chemoprevention of breast cancer: The Italian experience
26. Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women
27. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy
28. Estimation of proliferative activity in normal postmenopausal breast tissue using core biopsy
29. Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy
30. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis
31. Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy
32. Myoepithelial cells in the differential diagnosis of complex benign and malignant breast lesions: An immunohistochemical study
33. Investigation of a new pure antiestrogen (ICI 18278U) in women with primary breast cancer
34. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: Optimization of therapeutic dose and route
35. Perspectives on cancer chemoprevention research and drug development
36. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer
37. Influence of the antioestrogen tamoxifen on normal breast tissue
38. Oestrogen receptor expression in the normal and pre-cancerous breast
39. The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels
40. Tamoxifen alters levels of serum insulin-like growth factors and binding proteins in postmenopausal breast cancer patients: A prospective paired cohort study
41. A novel aromatase inhibitor, vorozole, shows antitumor activity and a decrease of tissue insulin-like growth factor-I level in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors
42. IGF-I physiology and breast cancer
43. Comparison of serum insulin-like growth factor-I and growth hormone levels in osteoporotic and non-osteoporotic postmenopausal women
44. Short-term effects of recombinant human insulin-like growth factor I on bone turnover in normal women
45. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients
46. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women
47. Aromatase inhibitors and their future role in post-menopausal women with early breast cancer
48. Serum crosslaps one step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen
49. Bone turnover markers and estradiol level in postmenopausal women
50. Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma
51. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in post- menopausal breast cancer patients: A Phase I study
52. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer